Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial von Shohdy, K.S., Pillai, M., Abbas, K.S., Allison, J., Waddell, T., Darlington, E., Mohammad, S., Hood, S., Atkinson, S., Simpson, K., Morgan, D., Nathan, P., Kilgour, E., Dive, C., Thistlethwaite, F.

Volltext

24P Somatic tumor testing informs on mismatch repair deficiency (MMR-D) phenotype in patients with endometrial cancer von Salib, M., Habib, H., Ebrahim, A.K.L.I.M., Shohdy, K.S.

Volltext

219P The landscape and prognostic impact of germline HLA-A subtypes in patients with advanced solid cancers von Shohdy, K.S., Atherton, J., Longland, J., Allison, J.L.E., Pillai, M., Thistlethwaite, F.

Volltext

LBA64 Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer: A multicentre registry study von Shohdy, K.S., Kassem, L., Gabriel, B.E.M., Lasheen, S., ElGhazawy, H., Barsoum, E.M., Elnahas, T., Azim, H.A.

Volltext

35P Prognostic impact of cytotoxic CD4 T cells (CD4 CTL) in tumour immune microenvironment of breast cancer patients von Shohdy, K.S., Almeldin, D.S., Ghaly, R., Kassem, L., Pagani, O.

Volltext

900P The emerging treatment options of plasmablastic lymphoma: Analysis of 173 individual patients’ outcomes von Makady, N.F.M., Shohdy, K.S., Ramzy, D., Abdel-Malek, R.R.

Volltext

34P Quadruple-negative breast cancer (PD-L1-negative triple-negative breast cancer, TNBC): Poorer response to chemotherapy and poorer survival compared to other TNBCs: A systematic... von Kassem, L., Shohdy, K.S., Elghazawy, H., Salib, M., Almeldin, D.S., Azim, H.A.

Volltext

1162P Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic... von Shohdy, K.S., Hatahet, Y., Gillham, T., Yacoub, E.T.T., Gupta, A., Gomes, F., Thistlethwaite, F., Blackhall, F., Lorigan, P., Cook, N.

Volltext

241P APOBEC3-induced PIK3CA mutations predict better clinical outcomes with PI3K inhibitors in patients with PIK3CA-mutated advanced breast cancer von Yacoub, E., Ayad, N.N., Abbas, K.S., Almeldin, D.S., Shohdy, K.S.

Volltext

1759MO Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study von Azim, H.A., Kassem, L., Shohdy, K.S., Safwat, Y., Khallaf, E., Naguib, S., Hegazy, M., Selim, A., Hussein, N., Abdelaziz, A.H., El Ghazaly, H.A., Hassany, M., Abdelaziz, A., Kandil, A.E.A., El Sayed, B.A., Hashem, T., Eid, S.S.M., Morsy, A., Abdelghaffar, K., Zaid, H.

Volltext

86O Serial monitoring of circulating tumor DNA (ctDNA) as a tumor-agnostic biomarker to inform clinical outcomes of patients receiving experimental cancer medicine von Shohdy, K.S., Franco, A. Ortega, Saud, A., Abdeltawab, R., Howell, M., Cook, N., Thistlethwaite, F., Graham, D.M., Carter, L., Darlington, E., Clipson, A., Rothwell, D., Dive, C., Krebs, M.G.

Volltext